Analytical issues regarding rosiglitazone meta-analysis
- PMID: 21263111
- DOI: 10.1001/archinternmed.2010.508
Analytical issues regarding rosiglitazone meta-analysis
Similar articles
-
Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.Am Heart J. 2008 Jul;156(1):23-30. doi: 10.1016/j.ahj.2008.03.002. Epub 2008 May 5. Am Heart J. 2008. PMID: 18585493 Review.
-
Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Clin Trials. 2008. PMID: 18375649
-
Rosiglitazone and cardiovascular risk.N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40. N Engl J Med. 2007. PMID: 17806135 No abstract available.
-
The rosiglitazone meta-analysis.Rev Cardiovasc Med. 2007 Spring;8(2):123-6. Rev Cardiovasc Med. 2007. PMID: 17603430 Review. No abstract available.
-
Faster publication isn't always better.Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):345. doi: 10.1038/ncpcardio0942. Nat Clin Pract Cardiovasc Med. 2007. PMID: 17589426 No abstract available.
Cited by
-
Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis.J Diabetes Investig. 2015 Jan;6(1):78-86. doi: 10.1111/jdi.12246. Epub 2014 Jun 18. J Diabetes Investig. 2015. PMID: 25621136 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical